{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:58:24Z","timestamp":1792241904768,"version":"4.4.0"},"reference-count":119,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2011,3,9]],"date-time":"2011-03-09T00:00:00Z","timestamp":1299628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openmedicinalchemistryjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOMCJ"],"published-print":{"date-parts":[[2011,3,9]]},"abstract":"<jats:p>Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002. Combination therapy is now explored in clinical trials as a new treatment approach for VL to reduce the length of treatment and potentially prevent selection of resistant parasites. However there is still a need for new drugs due to safety, resistance, stability and cost issues with existing therapies. The search for topical treatments for cutaneous leishmaniasis (CL) is ongoing. This review gives a brief overview of recent developments and approaches in anti-leishmanial drug discovery and development.<\/jats:p>","DOI":"10.2174\/1874104501105010031","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T05:40:36Z","timestamp":1300340436000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development"],"prefix":"10.2174","volume":"05","author":[{"given":"Karin","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","volume":"7","author":"Reithinger R","year":"2007","unstructured":"Reithinger R, Dujardin J C, Louzir H, Pirmez C, Alexander B, Brooker S. \n                Cutaneous leishmaniasis \n                Lancet Infect Dis  \n                2007; \n                7\n                : 581-96.","journal-title":"Lancet Infect. Dis"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.ijpara.2007.04.003","volume":"37","author":"Bates P A","year":"2007","unstructured":"Bates P A. \n                Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies \n                Int J Parasitol  \n                2007; \n                37\n                : 1097-6.","journal-title":"Int. J. Parasitol"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature02675","volume":"430","author":"Rogers M E","year":"2004","unstructured":"Rogers M E, Ilg T, Nikolaev A V, Ferguson M A, Bates P A. \n                Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG \n                Nature  \n                2004; \n                430\n                : 463-7.","journal-title":"Nature"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0020-7519(01)00259-4","volume":"31","author":"Burchmore R J","year":"2001","unstructured":"Burchmore R J, Barrett M P. \n                Life in vacuoles--nutrient acquisition by Leishmania amastigotes \n                Int J Parasitol  \n                2001; \n                31\n                : 1311-20.","journal-title":"Int. J. Parasitol"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1471-4922(02)02352-8","volume":"18","author":"Handman E","year":"2002","unstructured":"Handman E, Bullen D V. \n                Interaction of Leishmania with the host macrophage \n                Trends Parasitol  \n                2002; \n                18\n                : 332-4.","journal-title":"Trends Parasitol"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/bmb\/ldp046","volume":"93","author":"Feasey N","year":"2010","unstructured":"Feasey N, Wansbrough-Jones M, Mabey D C, Solomon A W. \n                Neglected tropical diseases \n                Br Med Bull  \n                2010; \n                93\n                : 179-200.","journal-title":"Br. Med. Bull"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.pt.2006.09.004","volume":"22","author":"Alvar J","year":"2006","unstructured":"Alvar J, Yactayo S, Bern C. \n                Leishmaniasis and poverty \n                Trends Parasitol  \n                2006; \n                22\n                : 552-7.","journal-title":"Trends Parasitol"},{"key":"refR8","first-page":"873","volume":"5","author":"Chappuis F","year":"2007","unstructured":"Chappuis F, Sundar S, Hailu A, et al. \n                Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat \n                Rev Microbiol  \n                2007; \n                5\n                : 873-2.","journal-title":"Rev. Microbiol"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"Croft S L","year":"2006","unstructured":"Croft S L, Sundar S, Fairlamb A H. \n                Drug resistance in leishmaniasis \n                Clin Microbiol Rev  \n                2006; \n                19\n                : 111-26.","journal-title":"Clin. Microbiol. Rev"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","volume":"31","author":"Sundar S","year":"2000","unstructured":"Sundar S, More D K, Singh M K, et al. \n                Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic \n                Clin Infect Dis  \n                2000; \n                31\n                : 1104-7.","journal-title":"Clin. Infect. Dis"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0065-308X(05)61006-8","volume":"61","author":"Alvar J","year":"2006","unstructured":"Alvar J, Croft S, Olliaro P. \n                Chemotherapy in the treatment and control of leishmaniasis \n                Adv Parasitol  \n                2006; \n                61\n                : 223-74.","journal-title":"Adv. Parasitol"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(05)70296-6","volume":"5","author":"Olliaro P L","year":"2005","unstructured":"Olliaro P L, Guerin P J, Gerstl S, Haaskjold A A, Rottingen J A, Sundar S. \n                Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004 \n                Lancet Infect Dis  \n                2005; \n                5\n                : 763-4.","journal-title":"Lancet Infect. Dis"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4269\/ajtmh.1998.59.139","volume":"59","author":"Sundar S","year":"1998","unstructured":"Sundar S, Sinha P R, Agrawal N K, et al. \n                A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate \n                Am J Trop Med Hyg  \n                1998; \n                59\n                : 139-43.","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0035-9203(88)90267-2","volume":"82","author":"Chulay J D","year":"1988","unstructured":"Chulay J D, Fleckenstein L, Smith D H. \n                Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate \n                Trans R Soc Trop Med Hyg  \n                1988; \n                82\n                : 69-72.","journal-title":"Trans. R. Soc. Trop. Med. Hyg"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-4017(97)00193-3","volume":"75","author":"Valladares J E","year":"1998","unstructured":"Valladares J E, Riera C, Alberola J, et al. \n                Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum \n                Vet Parasitol  \n                1998; \n                75\n                : 33-40.","journal-title":"Vet. Parasitol"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jinorgbio.2007.10.010","volume":"102","author":"Frezard F","year":"2008","unstructured":"Frezard F, Martins P S, Barbosa M C, et al. \n                New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate \n                J Inorg Biochem  \n                2008; \n                102\n                : 656-.","journal-title":"J. Inorg. Biochem"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/AAC.27.6.916","volume":"27","author":"Berman J D","year":"1985","unstructured":"Berman J D, Waddell D, Hanson B D. \n                Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate \n                Antimicrob Agents Chemother  \n                1985; \n                27\n                : 916-20.","journal-title":"Antimicrob. Agents. Chemother"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0006-2952(87)90689-7","volume":"36","author":"Berman J D","year":"1987","unstructured":"Berman J D, Gallalee J V, Best J M. \n                Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes \n                Biochem Pharmacol  \n                1987; \n                36\n                : 197-201.","journal-title":"Biochem. Pharmacol"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"39925","DOI":"10.1074\/jbc.M405635200","volume":"279","author":"Wyllie S","year":"2004","unstructured":"Wyllie S, Cunningham M L, Fairlamb A H. \n                Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani \n                J Biol Chem  \n                2004; \n                279\n                : 39925-2.","journal-title":"J. Biol. Chem"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","volume":"28","author":"Meyerhoff A US","year":"1999","unstructured":"Meyerhoff A US. \n                Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis \n                Clin Infect Dis  \n                1999; \n                28\n                : 42-8.","journal-title":"Clin. Infect. Dis"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","volume":"38","author":"Sundar S","year":"2004","unstructured":"Sundar S, Mehta H, Suresh A V, Singh S P, Rai M, Murray H W. \n                Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations \n                Clin Infect Dis  \n                2004; \n                38\n                : 377-83.","journal-title":"Clin. Infect. Dis"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","volume":"323","author":"Sundar S","year":"2001","unstructured":"Sundar S, Agrawal G, Rai M, Makharia M K, Murray H W. \n                Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial \n                BMJ  \n                2001; \n                323\n                : 419-22.","journal-title":"BMJ"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/377542","volume":"37","author":"Sundar S","year":"2003","unstructured":"Sundar S, Jha T K, Thakur C P, Mishra M, Singh V P, Buffels R. \n                Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study \n                Clin Infect Dis  \n                2003; \n                37\n                : 800-4.","journal-title":"Clin. Infect. Dis"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","volume":"362","author":"Sundar S","year":"2010","unstructured":"Sundar S, Chakravarty J, Agarwal D, Rai M, Murray H W. \n                Single-dose liposomal amphotericin B for visceral leishmaniasis in India \n                N Engl J Med  \n                2010; \n                362\n                : 504-12.","journal-title":"N. Engl. J. Med"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/500138","volume":"42","author":"Sundar S","year":"2006","unstructured":"Sundar S, Mehta H, Chhabra A, et al. \n                Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis \n                Clin Infect Dis  \n                2006; \n                42\n                : 608-13.","journal-title":"Clin. Infect. Dis"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4269\/ajtmh.2009.80.700","volume":"80","author":"Sundar S","year":"2009","unstructured":"Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, Chakravarty J. \n                Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis \n                Am J Trop Med Hyg  \n                2009; \n                80\n                : 700-3.","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1365-3156.2008.02128.x","volume":"13","author":"Sundar S","year":"2008","unstructured":"Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M. \n                Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar \n                Trop Med Int Health  \n                2008; \n                13\n                : 1208-.","journal-title":"Trop. Med. Int. Health"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-3156.2009.02306.x","volume":"14","author":"Olliaro P","year":"2009","unstructured":"Olliaro P, Darley S, Laxminarayan R, Sundar S. \n                Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India \n                Trop Med Int Health  \n                2009; \n                14\n                : 918-25.","journal-title":"Trop. Med. Int. Health"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","volume":"43","author":"Bern C","year":"2006","unstructured":"Bern C, Adler-Moore J, Berenguer J, et al. \n                Liposomal amphotericin B for the treatment of visceral leishmaniasis \n                Clin Infect Dis  \n                2006; \n                43\n                : 917-24.","journal-title":"Clin. Infect. Dis"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","volume":"49","author":"Adler-Moore J","year":"2002","unstructured":"Adler-Moore J, Proffitt R T. \n                AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience \n                J Antimicrob Chemother  \n                2002; \n                49\n                ((Suppl 1))\n                : 21-30.","journal-title":"J. Antimicrob. Chemother"},{"key":"refR31","unstructured":"Waqqas s. \n                WHO. \n                Report of a WHO informal consultation on liposomal amphotericin B in the treatment of visceral leishmaniasis WHO\/CDS\/NTD\/IDM\/20074  \n                2007; \n                4"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/10611869308996089","volume":"1","author":"Gradoni L","year":"1993","unstructured":"Gradoni L, Davidson R N, Orsini S, Betto P, Giambenedetti M. \n                Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice \n                J Drug Target  \n                1993; \n                1\n                : 311-6.","journal-title":"J. Drug Target"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/AAC.48.7.2409-2414.2004","volume":"48","author":"Pourshafie M","year":"2004","unstructured":"Pourshafie M, Morand S, Virion A, Rakotomanga M, Dupuy C, Loiseau P M. \n                Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes \n                Antimicrob Agents Chemother  \n                2004; \n                48\n                : 2409-14.","journal-title":"Antimicrob. Agents Chemother"},{"key":"refR34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","volume":"9","author":"Brajtburg J","year":"1996","unstructured":"Brajtburg J, Bolard J. \n                Carrier effects on biological activity of amphotericin B \n                Clin Microbiol Rev  \n                1996; \n                9\n                : 512-31.","journal-title":"Clin. Microbiol. Rev"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","volume":"100","author":"Sindermann H","year":"2006","unstructured":"Sindermann H, Engel J. \n                Development of miltefosine as an oral treatment for leishmaniasis \n                Trans R Soc Trop Med Hyg  \n                2006; \n                100\n                (Suppl 1)\n                : S17-20.","journal-title":"Trans. R. Soc. Trop. Med. Hyg"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","volume":"196","author":"Bhattacharya S K","year":"2007","unstructured":"Bhattacharya S K, Sinha P K, Sundar S, et al. \n                Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis \n                J Infect Dis  \n                2007; \n                196\n                : 591-8.","journal-title":"J. Infect. Dis"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.00014-08","volume":"52","author":"Dorlo T P","year":"2008","unstructured":"Dorlo T P, van Thiel P P, Huitema A D, et al. \n                Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients \n                Antimicrob Agents Chemother  \n                2008; \n                52\n                : 2855-60.","journal-title":"Antimicrob. Agents. Chemother"},{"key":"refR38","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1046\/j.1365-3156.2001.00795.x","volume":"6","author":"Bryceson A","year":"2001","unstructured":"Bryceson A. \n                A policy for leishmaniasis with respect to the prevention and control of drug resistance \n                Trop Med Int Health  \n                2001; \n                6\n                : 928-34.","journal-title":"Trop. Med. Int. Health"},{"key":"refR39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0924-8579(03)00125-0","volume":"22","author":"Seifert K","year":"2003","unstructured":"Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, Croft S L. \n                Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine) \n                Int J Antimicrob Agents  \n                2003; \n                22\n                : 380-7.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2007.05.007","volume":"30","author":"Seifert K","year":"2007","unstructured":"Seifert K, Perez-Victoria F J, Stettler M, et al. \n                Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo \n                Int J Antimicrob Agents  \n                2007; \n                30\n                : 229-35.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"49965","DOI":"10.1074\/jbc.M308352200","volume":"278","author":"Perez-Victoria F J","year":"2003","unstructured":"Perez-Victoria F J, Gamarro F, Ouellette M, Castanys S. \n                Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance \n                J Biol Chem  \n                2003; \n                278\n                : 49965-71.","journal-title":"J. Biol. Chem"},{"key":"refR42","doi-asserted-by":"crossref","first-page":"23766","DOI":"10.1074\/jbc.M605214200","volume":"281","author":"Perez-Victoria F J","year":"2006","unstructured":"Perez-Victoria F J, Sanchez-Canete M P, Castanys S, Gamarro F. \n                Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites \n                J Biol Chem  \n                2006; \n                281\n                : 23766-75.","journal-title":"J. Biol. Chem"},{"key":"refR43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drup.2006.04.001","volume":"9","author":"Perez-Victoria F J","year":"2006","unstructured":"Perez-Victoria F J, Sanchez-Canete M P, Seifert K, et al. \n                Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use \n                Drug Resist Updat  \n                2006; \n                9\n                : 26-39.","journal-title":"Drug. Resist. Updat"},{"key":"refR44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4899-0179-8_33","volume":"416","author":"Lux H","year":"1996","unstructured":"Lux H, Hart D T, Parker P J, Klenner T. \n                Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues \n                Adv Exp Med Biol  \n                1996; \n                416\n                : 201-11.","journal-title":"Adv. Exp. Med. Biol"},{"key":"refR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(00)00278-4","volume":"111","author":"Lux H","year":"2000","unstructured":"Lux H, Heise N, Klenner T, Hart D, Opperdoes F R. \n                Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania \n                Mol Biochem Parasitol  \n                2000; \n                111\n                : 1-14.","journal-title":"Mol. Biochem. Parasitol"},{"key":"refR46","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1128\/AAC.01415-06","volume":"51","author":"Luque-Ortega J R","year":"2007","unstructured":"Luque-Ortega J R, Rivas L. \n                Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes \n                Antimicrob Agents Chemother  \n                2007; \n                51\n                : 1327-32.","journal-title":"Antimicrob. Agents Chemother"},{"key":"refR47","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1128\/AAC.01123-06","volume":"51","author":"Rakotomanga M","year":"2007","unstructured":"Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau P M. \n                Miltefosine affects lipid metabolism in Leishmania donovani promastigotes \n                Antimicrob Agents  Chemother  \n                2007; \n                51\n                : 1425-30.","journal-title":"Antimicrob. Agents  Chemother"},{"key":"refR48","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","volume":"356","author":"Sundar S","year":"2007","unstructured":"Sundar S, Jha T K, Thakur C P, Sinha P K, Bhattacharya S K. \n                Injectable paromomycin for Visceral leishmaniasis in India \n                N Engl J Med  \n                2007; \n                356\n                : 2571-81.","journal-title":"N. Engl. J. Med"},{"key":"refR49","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1086\/605438","volume":"49","author":"Sundar S","year":"2009","unstructured":"Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. \n                Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment \n                Clin Infect Dis  \n                2009; \n                49\n                : 914-8.","journal-title":"Clin. Infect. Dis"},{"key":"refR50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.trstmh.2008.09.008","volume":"103","author":"Davidson R N","year":"2009","unstructured":"Davidson R N, den Boer M, Ritmeijer K. \n                Paromomycin \n                Trans R Soc Trop Med Hyg  \n                2009; \n                103\n                : 653-0.","journal-title":"Trans. R. Soc. Trop. Med. Hyg"},{"key":"refR51","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1371\/journal.pntd.0000432","volume":"3","author":"Ben Salah A","year":"2009","unstructured":"Ben Salah A, Buffet P A, Morizot G, et al. \n                WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study \n                PLoS Negl Trop Dis  \n                2009; \n                3\n                : e432.","journal-title":"PLoS Negl. Trop. Dis"},{"key":"refR52","first-page":"538","volume":"3","author":"Garnier T","year":"2002","unstructured":"Garnier T, Croft S L. \n                Topical treatment for cutaneous leishmaniasis \n                Curr Opin Investig Drugs  \n                2002; \n                3\n                : 538-44.","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"refR53","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1128\/AAC.41.5.982","volume":"41","author":"Kanyok T P","year":"1997","unstructured":"Kanyok T P, Killian A D, Rodvold K A, Danziger L H. \n                Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects \n                Antimicrob Agents Chemother  \n                1997; \n                41\n                : 982-6.","journal-title":"Antimicrob. Agents. Chemother"},{"key":"refR54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00931504","volume":"81","author":"Maarouf M","year":"1995","unstructured":"Maarouf M, Lawrence F, Croft S L, Robert-Gero M. \n                Ribosomes of Leishmania are a target for the aminoglycosides \n                Parasitol Res  \n                1995; \n                81\n                : 421-5.","journal-title":"Parasitol. Res"},{"key":"refR55","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/excr.1997.3500","volume":"232","author":"Maarouf M","year":"1997","unstructured":"Maarouf M, de Kouchkovsky Y, Brown S, Petit P X, Robert-Gero M. \n                In vivo interference of paromomycin with mitochondrial activity of Leishmania \n                Exp Cell Res  \n                1997; \n                232\n                : 339-48.","journal-title":"Exp. Cell. Res"},{"key":"refR56","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s004360050232","volume":"83","author":"Maarouf M","year":"1997","unstructured":"Maarouf M, Lawrence F, Brown S, Robert-Gero M. \n                Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes \n                Parasitol Res  \n                1997; \n                83\n                : 198-202.","journal-title":"Parasitol. Res"},{"key":"refR57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1051\/parasite\/1998052167","volume":"5","author":"Maarouf M","year":"1998","unstructured":"Maarouf M, Adeline M T, Solignac M, Vautrin D, Robert-Gero M. \n                Development and characterization of paromomycin-resistant Leishmania donovani promastigotes \n                Parasite  \n                1998; \n                5\n                : 167-73.","journal-title":"Parasite"},{"key":"refR58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","volume":"164","author":"Jhingran A","year":"2009","unstructured":"Jhingran A, Chawla B, Saxena S, Barrett M P, Madhubala R. \n                Paromomycin: uptake and resistance in Leishmania donovani \n                Mol Biochem Parasitol  \n                2009; \n                164\n                : 111-7.","journal-title":"Mol. Biochem. Parasitol"},{"key":"refR59","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1550-7408.1983.tb01421.x","volume":"30","author":"Langreth S G","year":"1983","unstructured":"Langreth S G, Berman J D, Riordan G P, Lee L S. \n                Fine-structural alterations in Leishmania tropica within human macrophages exposed to antileishmanial drugs in vitro \n                J Protozool  \n                1983; \n                30\n                : 555-61.","journal-title":"J. Protozool"},{"key":"refR60","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00034983.1982.11687502","volume":"76","author":"Croft S L","year":"1982","unstructured":"Croft S L, Brazil R P. \n                Effect of pentamidine isethionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro \n                Ann Trop Med Parasitol  \n                1982; \n                76\n                : 37-43.","journal-title":"Ann. Trop. Med. Parasitol"},{"key":"refR61","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/bj2840463","volume":"284","author":"Vercesi A E","year":"1992","unstructured":"Vercesi A E, Docampo R. \n                Ca2+ transport by digitoninpermeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ \n                Biochem J  \n                1992; \n                284\n                : 463-7.","journal-title":"Biochem. J"},{"key":"refR62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0014-5793(00)01531-3","volume":"473","author":"Vercesi A E","year":"2000","unstructured":"Vercesi A E, Rodrigues C O, Catisti R, Docampo R. \n                Presence of a Na(+)\/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs \n                FEBS Lett  \n                2000; \n                473\n                : 203-6.","journal-title":"FEBS Lett"},{"key":"refR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molbiopara.2005.08.016","volume":"145","author":"Mukherjee A","year":"2006","unstructured":"Mukherjee A, Padmanabhan P K, Sahani M H, Barrett M P, Madhubala R. \n                Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani \n                Mol Biochem Parasitol  \n                2006; \n                145\n                : 1-10.","journal-title":"Mol. Biochem. Parasitol"},{"key":"refR64","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1128\/AAC.46.12.3731-3738.2002","volume":"46","author":"Basselin M","year":"2002","unstructured":"Basselin M, Denise H, Coombs G H, Barrett M P. \n                Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion \n                Antimicrob Agents Chemother  \n                2002; \n                46\n                : 3731-8.","journal-title":"Antimicrob. Agents. Chemother"},{"key":"refR65","first-page":"1446","volume":"3","author":"Yeates C","year":"2002","unstructured":"Yeates C. \n                Sitamaquine (GlaxoSmithKline\/Walter Reed Army Institute) \n                Curr Opin Investig Drugs  \n                2002; \n                3\n                : 1446-52.","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"refR66","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/QCO.0b013e328010b848","volume":"19","author":"Tekwani B L","year":"2006","unstructured":"Tekwani B L, Walker L A. \n                8-Aminoquinolines: future role as antiprotozoal drugs \n                Curr Opin Infect Dis  \n                2006; \n                19\n                : 623-31.","journal-title":"Curr. Opin. Infect. Dis"},{"key":"refR67","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4269\/ajtmh.2005.73.871","volume":"73","author":"Wasunna M K","year":"2005","unstructured":"Wasunna M K, Rashid J R, Mbui J, et al. \n                A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya \n                Am J Trop Med Hyg  \n                2005; \n                73\n                : 871-6.","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"refR68","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4269\/ajtmh.2005.73.1005","volume":"73","author":"Jha T K","year":"2005","unstructured":"Jha T K, Sundar S, Thakur C P, Felton J M, Sabin A J, Horton J. \n                A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India \n                Am J Trop Med Hyg  \n                2005; \n                73\n                : 1005-1.","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"refR69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0006-2952(85)90122-4","volume":"34","author":"Theoharides A D","year":"1985","unstructured":"Theoharides A D, Chung H, Velazquez H. \n                Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes \n                Biochem Pharmacol  \n                1985; \n                34\n                : 181-8.","journal-title":"Biochem. Pharmacol"},{"key":"refR70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0090-9556(25)06501-8","volume":"23","author":"Idowu O R","year":"1995","unstructured":"Idowu O R, Peggins J O, Brewer T G. \n                Side-chain hydroxylation in the metabolism of 8-aminoquinoline antiparasitic agents \n                Drug Metab Dispos  \n                1995; \n                23\n                : 18-27.","journal-title":"Drug. Metab. Dispos"},{"key":"refR71","first-page":"136","volume":"Spec No 3","author":"Taylor T","year":"1991","unstructured":"Taylor T, Hawkins D R, Morris G R, Chung H. \n                Pharmacokinetics of the anti-leishmanian agent WR 6026 in dogs \n                Eur J Drug Metab Pharmacokinet  \n                1991; \n                Spec No 3\n                : 136-9.","journal-title":"Eur. J. Drug. Metab. Pharmacokinet"},{"key":"refR72","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1128\/AAC.00964-08","volume":"52","author":"Lopez-Martin C","year":"2008","unstructured":"Lopez-Martin C, Perez-Victoria J M, Carvalho L, Castanys S, Gamarro F. \n                Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes \n                Antimicrob Agents Chemother  \n                2008; \n                52\n                : 4030-6.","journal-title":"Antimicrob. Agents Chemother"},{"key":"refR73","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbamem.2006.07.003","volume":"1768","author":"Duenas-Romero A M","year":"2007","unstructured":"Duenas-Romero A M, Loiseau P M, Saint-Pierre-Chazalet M. \n                Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes \n                Biochim Biophys Acta  \n                2007; \n                1768\n                : 246-52.","journal-title":"Biochim. Biophys. Acta"},{"key":"refR74","first-page":"399","volume":"123","author":"Croft S L","year":"2006","unstructured":"Croft S L, Seifert K, Yardley V. \n                Current scenario of drug development for leishmaniasis \n                Indian J Med Res  \n                2006; \n                123\n                : 399-410.","journal-title":"Indian J. Med Res"},{"key":"refR75","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.37.4.859","volume":"37","author":"Fournet A","year":"1993","unstructured":"Fournet A, Barrios A A, Munoz V, Hocquemiller R, Cave A, Bruneton J. \n                2-substituted quinoline alkaloids as potential antileishmanial drugs \n                Antimicrob Agents Chemother  \n                1993; \n                37\n                : 859-63.","journal-title":"Antimicrob. Agents. Chemother"},{"key":"refR76","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/jac\/33.3.537","volume":"33","author":"Fournet A","year":"1994","unstructured":"Fournet A, Gantier J C, Gautheret A, et al. \n                The activity of 2-substituted quinoline alkaloids in BALB\/c mice infected with Leishmania donovani \n                J Antimicrob Chemother  \n                1994; \n                33\n                : 537-44.","journal-title":"J. Antimicrob. Chemother"},{"key":"refR77","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1016\/j.bmc.2003.09.007","volume":"11","author":"Fakhfakh M A","year":"2003","unstructured":"Fakhfakh M A, Fournet A, Prina E, et al. \n                Synthesis and biological evaluation of substituted quinolines: potential treatment of protozoal and retroviral co-infections \n                Bioorg Med Chem  \n                2003; \n                11\n                : 5013-23.","journal-title":"Bioorg. Med. Chem"},{"key":"refR78","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1128\/AAC.49.12.4950-4956.2005","volume":"49","author":"Nakayama H","year":"2005","unstructured":"Nakayama H, Loiseau P M, Bories C, et al. \n                Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases \n                Antimicrob Agents Chemother  \n                2005; \n                49\n                : 4950-6.","journal-title":"Antimicrob. Agents Chemother"},{"key":"refR79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tox.2007.03.003","volume":"235","author":"Desrivot J","year":"2007","unstructured":"Desrivot J, Edlund P O, Svensson R, et al. \n                Metabolism of 2-substituted quinolines with antileishmanial activity studied in vitro with liver microsomes, hepatocytes and recombinantly expressed enzymes analyzed by LC\/MS \n                Toxicology  \n                2007; \n                235\n                : 27-38.","journal-title":"Toxicology"},{"key":"refR80","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.biopha.2007.03.004","volume":"61","author":"Desrivot J","year":"2007","unstructured":"Desrivot J, Herrenknecht C, Ponchel G, et al. \n                Antileishmanial 2-substituted quinolines: in vitro behaviour towards biological components \n                Biomed Pharmacother  \n                2007; \n                61\n                : 441-50.","journal-title":"Biomed. Pharmacother"},{"key":"refR81","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/AAC.00645-07","volume":"52","author":"Nanayakkara N P","year":"2008","unstructured":"Nanayakkara N P, Ager A L, Bartlett M S Jr, et al. \n                Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy ]quinoline succinate \n                Antimicrob Agents Chemother  \n                2008; \n                52\n                : 2130-7.","journal-title":"Antimicrob. Agents Chemother"},{"key":"refR82","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1016\/j.bmc.2005.04.034","volume":"13","author":"Jain M","year":"2005","unstructured":"Jain M, Khan S I, Tekwani B L, et al. \n                Synthesis, antimalarial, antileishmanial, and antimicrobial activities of some 8-quinolinamine analogues \n                Bioorg Med Chem  \n                2005; \n                13\n                : 4458-66.","journal-title":"Bioorg. Med. Chem"},{"key":"refR83","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bmc.2006.10.036","volume":"15","author":"Kaur K","year":"2007","unstructured":"Kaur K, Patel S R, Patil P, et al. \n                Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-quinolinamines \n                Bioorg Med Chem  \n                2007; \n                15\n                : 915-30.","journal-title":"Bioorg. Med. Chem"},{"key":"refR84","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/30.6.827","volume":"30","author":"Croft S L","year":"1992","unstructured":"Croft S L, Hogg J, Gutteridge W E, Hudson A T, Randall A W. \n                The activity of hydroxynaphthoquinones against Leishmania donovani \n                J Antimicrob Chemother  \n                1992; \n                30\n                : 827-32.","journal-title":"J Antimicrob Chemother"},{"key":"refR85","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/jm030868a","volume":"47","author":"Mantyla A","year":"2004","unstructured":"Mantyla A, Garnier T, Rautio J, et al. \n                Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. \n                J Med Chem  \n                2004; \n                47\n                : 188-95.","journal-title":"J. Med. Chem"},{"key":"refR86","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1016\/j.bmc.2004.04.032","volume":"12","author":"Mantyla A","year":"2004","unstructured":"Mantyla A, Rautio J, Nevalainen T, et al. \n                Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives \n                Bioorg Med Chem  \n                2004; \n                12\n                : 3497-502.","journal-title":"Bioorg. Med. Chem"},{"key":"refR87","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1211\/jpp.59.1.0006","volume":"59","author":"Garnier T","year":"2007","unstructured":"Garnier T, Mantyla A, Jarvinen T, Lawrence M J, Brown M B, Croft S L. \n                Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis \n                J Pharm Pharmacol  \n                2007; \n                59\n                : 41-9.","journal-title":"J. Pharm. Pharmacol"},{"key":"refR88","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dkm303","volume":"60","author":"Garnier T","year":"2007","unstructured":"Garnier T, Mantyla A, Jarvinen T, Lawrence J, Brown M, Croft S. \n                In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs \n                J Antimicrob Chemother  \n                2007; \n                60\n                : 802-10.","journal-title":"J. Antimicrob. Chemother"},{"key":"refR89","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jac\/dkn189","volume":"62","author":"Manandhar K D","year":"2008","unstructured":"Manandhar K D, Yadav T P, Prajapati V K, et al. \n                Antileishmanial activity of nano-amphotericin B deoxycholate \n                J Antimicrob Chemother  \n                2008; \n                62\n                : 376-80.","journal-title":"J. Antimicrob. Chemother"},{"key":"refR90","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/600105","volume":"200","author":"Wasan K M","year":"2009","unstructured":"Wasan K M, Wasan E K, Gershkovich P, et al. \n                Highly effective oral amphotericin B formulation against murine visceral leishmaniasis \n                J Infect Dis  \n                2009; \n                200\n                : 357-60.","journal-title":"J. Infect. Dis"},{"key":"refR91","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijantimicag.2008.10.013","volume":"33","author":"Nicoletti S","year":"2009","unstructured":"Nicoletti S, Seifert K, Gilbert I H. \n                N-(2-hydroxypropyl)methacrylamide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents \n                Int J Antimicrob Agents  \n                2009; \n                33\n                : 441-8.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"refR92","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.bmc.2010.02.043","volume":"18","author":"Nicoletti S","year":"2010","unstructured":"Nicoletti S, Seifert K, Gilbert I H. \n                Water-soluble polymer-drug conjugates for combination chemotherapy against visceral leishmaniasis \n                Bioorg Med Chem  \n                2010; \n                18\n                : 2559-65.","journal-title":"Bioorg. Med. Chem"},{"key":"refR93","first-page":"398","volume":"120","author":"Jawahar M S","year":"2004","unstructured":"Jawahar M S. \n                Current trends in chemotherapy of tuberculosis \n                Indian J Med Res  \n                2004; \n                120\n                : 398-417.","journal-title":"Indian J. Med. Res"},{"key":"refR94","first-page":"395","volume":"52","author":"Ellard G A","year":"1984","unstructured":"Ellard G A. \n                Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs \n                Int J Lepr Other Mycobact Dis  \n                1984; \n                52\n                : 395-401.","journal-title":"Int. J. Lepr. Other Mycobact. Dis"},{"key":"refR95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clindermatol.2006.05.012","volume":"25","author":"Walker S L","year":"2007","unstructured":"Walker S L, Lockwood D N. \n                Leprosy \n                Clin Dermatol  \n                2007; \n                25\n                : 165-72.","journal-title":"Clin. Dermatol"},{"key":"refR96","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(04)16680-4","volume":"364","author":"Kremsner P G","year":"2004","unstructured":"Kremsner P G, Krishna S. \n                Antimalarial combinations \n                Lancet  \n                2004; \n                364\n                : 285-94.","journal-title":"Lancet"},{"key":"refR97","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","volume":"47","author":"Sundar S","year":"2008","unstructured":"Sundar S, Rai M, Chakravarty J, et al. \n                New Treatment Approach in Indian Visceral Leishmaniasis: Single-Dose Liposomal Amphotericin B Followed by Short-Course Oral Miltefosine \n                Clin Infect Dis  \n                2008; \n                47\n                : 1000-6.","journal-title":"Clin. Infect. Dis"},{"key":"refR98","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4269\/ajtmh.2007.77.89","volume":"77","author":"Melaku Y","year":"2007","unstructured":"Melaku Y, Collin S M, Keus K, Gatluak F, Ritmeijer K, Davidson R N. \n                Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy \n                Am J Trop Med Hyg  \n                2007; \n                77\n                : 89-94.","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"refR99","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ijpara.2007.04.008","volume":"37","author":"Wiese M","year":"2007","unstructured":"Wiese M. \n                Leishmania MAP kinases--familiar proteins in an unusual context \n                Int J Parasitol  \n                2007; \n                37\n                : 1053-62.","journal-title":"Int. J. Parasitol"},{"key":"refR100","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1128\/AAC.48.8.3033-3042.2004","volume":"48","author":"Grant K M","year":"2004","unstructured":"Grant K M, Dunion M H, Yardley V, et al. \n                Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity \n                Antimicrob Agents Chemother  \n                2004; \n                48\n                : 3033-42.","journal-title":"Antimicrob. Agents Chemother"},{"key":"refR101","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.ijpara.2009.04.005","volume":"39","author":"Xingi E","year":"2009","unstructured":"Xingi E, Smirlis D, Myrianthopoulos V, et al. \n                6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis \n                Int J Parasitol  \n                2009; \n                39\n                : 1289-303.","journal-title":"Int. J. Parasitol"},{"key":"refR102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbapap.2005.08.018","volume":"1754","author":"Naula C","year":"2005","unstructured":"Naula C, Parsons M, Mottram J C. \n                Protein kinases as drug targets in trypanosomes and Leishmania \n                Biochim Biophys Acta  \n                2005; \n                1754\n                : 151-9.","journal-title":"Biochim. Biophys. Acta"},{"key":"refR103","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.pt.2010.04.012","volume":"26","author":"Dujardin J C","year":"2010","unstructured":"Dujardin J C, Gonzalez-Pacanowska D, Croft S L, Olesen O F, Spath G F. \n                Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas \n                Trends Parasitol  \n                2010; \n                26\n                : 395-403.","journal-title":"Trends Parasitol"},{"key":"refR104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.cdd.4402232","volume":"15","author":"Ambit A","year":"2008","unstructured":"Ambit A, Fasel N, Coombs G H, Mottram J C. \n                An essential role for the Leishmania major metacaspase in cell cycle progression \n                Cell Death Differ  \n                2008; \n                15\n                : 113-22.","journal-title":"Cell Death Differ"},{"key":"refR105","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jinorgbio.2008.05.010","volume":"102","author":"Fricker S P","year":"2008","unstructured":"Fricker S P, Mosi R M, Cameron B R, et al. \n                Metal compounds for the treatment of parasitic diseases \n                J Inorg Biochem  \n                2008; \n                102\n                : 1839-45.","journal-title":"J. Inorg. Biochem"},{"key":"refR106","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/jm901178d","volume":"53","author":"Bakunov S A","year":"2010","unstructured":"Bakunov S A, Bakunova S M, Wenzler T, et al. \n                Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles \n                J Med Chem  \n                2010; \n                53\n                : 254-72.","journal-title":"J. Med. Chem"},{"key":"refR107","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1016\/j.ejmech.2009.03.014","volume":"44","author":"Patrick D A","year":"2009","unstructured":"Patrick D A, Bakunov S A, Bakunova S M, et al. \n                Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes \n                Eur J Med Chem  \n                2009; \n                44\n                : 3543-51.","journal-title":"Eur. J. Med. Chem"},{"key":"refR108","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.biochi.2008.02.017","volume":"90","author":"Wilson W D","year":"2008","unstructured":"Wilson W D, Tanious F A, Mathis A, Tevis D, Hall J E, Boykin D W. \n                Antiparasitic compounds that target DNA \n                Biochimie  \n                2008; \n                90\n                : 999-1014.","journal-title":"Biochimie"},{"key":"refR109","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1128\/AAC.48.8.2937-2950.2004","volume":"48","author":"Lorente S O","year":"2004","unstructured":"Lorente S O, Rodrigues J C, Jimenez Jimenez C, et al. \n                Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis \n                Antimicrob Agents Chemother  \n                2004; \n                48\n                : 2937-50.","journal-title":"Antimicrob. Agents Chemother"},{"key":"refR110","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1016\/j.bmc.2005.06.012","volume":"13","author":"Lorente S O","year":"2005","unstructured":"Lorente S O, Jimenez C J, Gros L, et al. \n                Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics \n                Bioorg Med Chem  \n                2005; \n                13\n                : 5435-3.","journal-title":"Bioorg. Med. Chem"},{"key":"refR111","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.bmc.2009.06.062","volume":"17","author":"Gigante F","year":"2009","unstructured":"Gigante F, Kaiser M, Brun R, Gilbert I H. \n                SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents \n                Bioorg Med Chem  \n                2009; \n                17\n                : 5950-61.","journal-title":"Bioorg. Med. Chem"},{"key":"refR112","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1128\/AAC.00205-07","volume":"51","author":"Cammerer S B","year":"2007","unstructured":"Cammerer S B, Jimenez C, Jones S, et al. \n                Quinuclidine derivatives as potential antiparasitics \n                Antimicrob Agents Chemother  \n                2007; \n                51\n                : 4049-61.","journal-title":"Antimicrob. Agents Chemother"},{"key":"refR113","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.pt.2007.08.019","volume":"23","author":"Frearson J A","year":"2007","unstructured":"Frearson J A, Wyatt P G, Gilbert I H, Fairlamb A H. \n                Target assessment for antiparasitic drug discovery \n                Trends Parasitol  \n                2007; \n                23\n                : 589-95.","journal-title":"Trends Parasitol"},{"key":"refR114","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nchembio837","volume":"2","author":"Renslo A R","year":"2006","unstructured":"Renslo A R, McKerrow J H. \n                Drug discovery and development for neglected parasitic diseases \n                Nat Chem Biol  \n                2006; \n                2\n                : 701-10.","journal-title":"Nat. Chem. Biol"},{"key":"refR115","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/449166a","volume":"449","author":"Hopkins A L","year":"2007","unstructured":"Hopkins A L, Witty M J, Nwaka S. \n                Mission possible \n                Nature  \n                2007; \n                449\n                : 166-9.","journal-title":"Nature"},{"key":"refR116","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nrd2684","volume":"7","author":"Aguero F","year":"2008","unstructured":"Aguero F, Al-Lazikani B, Aslett M, et al. \n                Genomic-scale prioritization of drug targets: the TDR Targets database \n                Nat Rev Drug Discov  \n                2008; \n                7\n                : 900-7.","journal-title":"Nat. Rev. Drug Discov"},{"key":"refR117","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd2144","volume":"5","author":"Nwaka S","year":"2006","unstructured":"Nwaka S, Hudson A. \n                Innovative lead discovery strategies for tropical diseases \n                Nat Rev Drug Discov  \n                2006; \n                5\n                : 941-55.","journal-title":"Nat. Rev. Drug Discov"},{"key":"refR118","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1371\/journal.pntd.0000440","volume":"3","author":"Nwaka S","year":"2009","unstructured":"Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. \n                Advancing drug innovation for neglected diseases-criteria for lead progression \n                PLoS Negl Trop Dis  \n                2009; \n                3\n                : e440.","journal-title":"PLoS Negl. Trop. Dis"},{"key":"refR119","doi-asserted-by":"crossref","unstructured":"Don R, Chatelain E. \n                \n                Drug Discovery for Neglected Diseaes: View of a public private partnership In: Paul Selzer, Ed. \n                In: Antiparasitic and antibacterial drug discovery From molecular targets to drug candidates.  \n                Weinheim: Wiley-VCH Verlag GmbH & Co KGaA 2009; pp. \n                \n                \n                33-43.","DOI":"10.1002\/9783527626816.ch3"}],"container-title":["The Open Medicinal Chemistry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openmedicinalchemistryjournal.com\/contents\/volumes\/V05\/TOMCJ-5-31\/TOMCJ-5-31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openmedicinalchemistryjournal.com\/contents\/volumes\/V05\/TOMCJ-5-31\/TOMCJ-5-31.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openmedicinalchemistryjournal.com\/contents\/volumes\/V05\/TOMCJ-5-31\/TOMCJ-5-31.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T11:51:18Z","timestamp":1761306678000},"score":1,"resource":{"primary":{"URL":"https:\/\/openmedicinalchemistryjournal.com\/VOLUME\/05\/PAGE\/31\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,9]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3,9]]}},"alternative-id":["TOMCJ-5-31"],"URL":"https:\/\/doi.org\/10.2174\/1874104501105010031","relation":{},"ISSN":["1874-1045"],"issn-type":[{"value":"1874-1045","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2010-2-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-5-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-6-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}